Graft-versus-host disease: current understanding of immune pathogenesis and clinical treatment
Graft-versus-host disease: current understanding of immune pathogenesis and clinical treatment
复制标题
移植物抗宿主病：免疫发病机制和临床治疗的最新认识
DOI：
10.11406/rinketsu.62.1281
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
松岡賢市
中科院分区：
文献类型：
--
作者：
Yanada M;Konuma T;Yamasaki S;Mizuno S;Hirabayashi S;Nishiwaki S;Uchida N;Doki N;Tanaka M;Ozawa Y;Sawa M;Eto T;Kawakita T;Ota S;Fukuda T;Onizuka M;Kimura T;Atsuta Y;Kako S;Yano S;松岡賢市
移植物抗宿主病(GVHD)是异基因造血干细胞移植(HSCT)后的主要并发症。虽然同种异体免疫反应可能导致移植物抗宿主病，但它也在由此产生的抗肿瘤效应和促进植入方面发挥重要作用。因此，根据每个患者的病情在适当的时间应用必要的、充分的免疫控制是HSCT成功的关键。近年来，由于移植移植物的多样化以及新的免疫抑制方法和免疫调节剂的出现，HSCT的格局发生了巨大的变化。本文首先介绍急、慢性移植物抗宿主病免疫发病机制的研究现状，然后讨论各种异基因造血干细胞移植后移植物抗宿主病的特点及治疗干预。
Graft-versus-host disease (GVHD) is a major complication that occurs after allogeneic hematopoietic stem cell transplantation (HSCT). While the allogeneic immune response may cause GVHD, it also plays essential roles in the resultant antitumor effects and in engraftment facilitation. Therefore, the application of necessary and sufficient immune control at an appropriate time according to the condition of each individual patient is the key to successful HSCT. Recently, the landscape of HSCT has changed drastically due to the diversification of transplanted grafts and the emergence of novel immunosuppressive methods and immune-modulatory agents. In this review, we first describe the current understanding of the immune pathogenesis of acute and chronic GVHD, and then, we discuss the characterization and therapeutic intervention for GVHD after diversified HSCT.